AI Triage vs AI Report Drafting: What Aidoc's First Read News Actually Means for Radiologists

In late June 2026, the FDA granted Breakthrough Device designation to Aidoc's First Read, a tool that drafts preliminary report text for chest radiographs. The news made the rounds under headlines like "AI drafts radiology reports," and it generated a predictable amount of confusion — partly because two genuinely different categories of radiology AI keep getting described with the same words, and partly because "Breakthrough designation" sounds like an approval and is not one.

This guide separates the two product categories, explains what the designation actually means, and lays out what the announcement signals about where reporting is heading. We build a report-drafting assistant ourselves, so we have a stake in this market — that disclosure is repeated where it matters below.

Two different kinds of "AI reads the scan"

Detection and triage AI

This is the category Aidoc built its business in, alongside companies like Viz.ai. Triage software runs in the background, analyzes studies as they arrive, and reprioritizes the worklist — a suspected intracranial hemorrhage or pulmonary embolism gets flagged so the radiologist opens it before the routine follow-up that arrived first.

Two things define the category. First, it is device software: it makes (or materially informs) a detection claim about a specific finding, so each indication goes through FDA premarket review, typically 510(k) clearance. Aidoc received its first such clearance in 2018, for triage of intracranial hemorrhage on head CT, and has been accumulating cleared indications since — in January 2026 the FDA cleared eleven new emergency-department triage indications on its CARE foundation model, bringing its abdominal CT indications to fourteen in one workflow.

Second, triage AI does not touch the report. It changes the order you read in and can shorten time-to-treatment for time-critical findings. The documentation work — composing findings, applying guidelines, writing the impression — is untouched. When the flagged study opens, you still start from a blank dictation.

Report-drafting assistants

The second category starts where triage ends. A report-drafting assistant takes the inputs of a case — images, prior reports, clinical history, your dictation — and produces a draft of the report itself, which the radiologist reviews, edits, and signs. The claim is a documentation claim, not a detection claim: the output is a starting draft under mandatory radiologist review, not an autonomous diagnosis.

The categories are not competitors. Triage decides which study you open next; a drafting assistant changes what you start from when you open it. A practice can run both, and the time savings stack rather than overlap.

What made the First Read announcement notable is that Aidoc — the most established name in the first category — is now formally building in the second, and framing the output as device software that will go through FDA review.

Designation is not clearance

The FDA Breakthrough Devices Program, created by the 21st Century Cures Act of 2016, gives a device sponsor prioritized review, a more interactive relationship with FDA reviewers, and senior-level engagement during development. It exists to speed up the process for novel devices addressing serious conditions.

What it does not do:

• It is not a clearance or approval. A designated device is still investigational and cannot be marketed until it completes the normal premarket pathway.
• It does not lower the evidence bar. The statutory standard for 510(k) clearance, De Novo classification, or PMA approval is unchanged; the designation changes the speed and quality of FDA interaction, not the proof required.
• It is not a prediction of success. Per figures reported in Health Affairs, as of mid-2023 the FDA had granted 839 Breakthrough designations, and only 81 of those devices had gone on to be cleared, approved, or granted De Novo classification. Most designated devices were still somewhere in development.

So the accurate reading of the June news is: Aidoc has told the FDA what First Read is, the FDA has agreed it is novel and important enough to merit an expedited review relationship, and the product now has a faster lane through a review it has not yet completed. First Read is not on the market, and no one — including Aidoc — can currently say when it will be.

What First Read actually is

Sticking to what Aidoc and the trade press have stated:

• First Read analyzes chest radiographs and drafts preliminary report text for them. Chest X-ray only — not CT, MRI, ultrasound, or other modalities.
• It is expected to generate preliminary reports covering more than 100 pre-specified findings; Aidoc has declined to publish the full list while the product remains premarket.
• A radiologist must review and sign every report. Aidoc has been consistent that this is an efficiency tool under physician oversight, not autonomous interpretation.
• It builds on the same underlying architecture as Aidoc's FDA-cleared CT triage products.

That is a serious, credible entry into report drafting from a well-funded company with real regulatory experience, and it deserves to be taken at face value rather than dismissed or hyped.

What this signals

Three things, in our reading.

Report drafting is now the acknowledged frontier. The triage market is maturing — the detection indications are increasingly cleared, deployed, and commoditized — and the largest remaining time cost in radiology is the report itself. When the leading triage vendor spends its regulatory capital on a drafting product, that is a statement about where the value is.

Regulators are engaging rather than blocking. Breakthrough designation for a generative drafting tool means the FDA considers "AI drafts, radiologist signs" a reviewable device concept, not a non-starter. Aidoc is not alone in that lane: Becker's reported that Mosaic Clinical Technologies, a Radiology Partners subsidiary, received the same designation in March 2026 for its Cognita chest X-ray reporting tool.

The radiologist-in-the-loop model won the argument. Every serious entrant — Aidoc included — frames drafting AI as preliminary text under mandatory physician review. Nobody credible is proposing unsigned AI reports.

Where MyRadAgent sits

We build MyRadAgent, so read this section knowing that.

MyRadAgent is in the second category: a report-drafting assistant, positioned as documentation support, not autonomous diagnosis. The practical differences from what Aidoc has described for First Read:

• All modalities, available now. MyRadAgent drafts across CT, MRI, ultrasound, radiography, and mammography today, rather than a single modality pending regulatory review.
• It learns your style. Every correction you make feeds a per-user learning loop — your templates, phrasing, and hedging conventions — so drafts converge on how you actually report.
• You review and sign everything. Same principle Aidoc states: the radiologist is the author of record, and the draft is a starting point.

And to be plain about the other direction: MyRadAgent is complementary to triage AI, not a replacement for it. We do not reprioritize worklists or make time-critical detection claims; if your practice benefits from Aidoc's or Viz.ai's triage, a drafting assistant sits alongside it. If First Read ships, it will validate the category we work in, and that is fine with us.

If you want to see what a drafting assistant feels like on your own cases, the live demo is here.

The short version

Triage AI decides what you read next; drafting AI writes your first draft. Aidoc's First Read is a chest X-ray drafting tool that earned an expedited FDA review pathway in June 2026 — a meaningful signal, not a product launch. The direction of the market is clear: AI drafts, radiologists sign.

Sources

• Radiology Business — Aidoc's chest X-ray reporting tool earns FDA Breakthrough Device designation
• AuntMinnie — FDA grants Aidoc Breakthrough Device Designation for chest x-ray AI
• MedTech Dive — Aidoc wins breakthrough nod for AI that reads chest X-rays
• MobiHealthNews — Aidoc lands FDA breakthrough status; AI drafts radiology reports
• Becker's Hospital Review — FDA backs 2 generative AI radiology platforms
• BioWorld — FDA clears 11 Aidoc AI triage indications
• BioSpace — Aidoc receives FDA clearance to triage patients using AI (2018)
• Health Affairs — FDA Breakthrough Device Designation, clinical evidence, and Medicare payment policies